Losartan, an indirect TGF-β inhibitor, shows potential in reducing fibrosis in human organs [161], with an ongoing phase II trial evaluating its effectiveness in EoE (NCT03029091). The gene discussed is TGFB1; the disease is eosinophilic esophagitis.